메뉴 건너뛰기




Volumn 60, Issue 4, 2016, Pages 2336-2342

Pharmacodynamics of voriconazole in children: Further steps along the path to true individualized therapy

Author keywords

[No Author keywords available]

Indexed keywords

GALACTOMANNAN; VORICONAZOLE; ANTIFUNGAL AGENT; BIOLOGICAL MARKER; FUNGAL POLYSACCHARIDE; MANNAN;

EID: 84963690287     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.03023-15     Document Type: Article
Times cited : (32)

References (21)
  • 1
    • 77952547165 scopus 로고    scopus 로고
    • Therapy for fungal diseases: Opportunities and priorities
    • Denning DW, Hope WW. 2010. Therapy for fungal diseases: opportunities and priorities. Trends Microbiol 18:195-204. http://dx.doi.org/10.1016/j.tim.2010.02.004.
    • (2010) Trends Microbiol , vol.18 , pp. 195-204
    • Denning, D.W.1    Hope, W.W.2
  • 2
    • 84903465253 scopus 로고    scopus 로고
    • Fourth European Conference on Infections in Leukaemia (ECIL-4): Guidelines for diagnosis, prevention, and treatment of invasive fungal diseases in paediatric patients with cancer or allogeneic haemopoietic stem-cell transplantation
    • Groll AH, Castagnola E, Cesaro S, Dalle J-H, Engelhard D, Hope W, Roilides E, Styczynski J, Warris A, Lehrnbecher T. 2014. Fourth European Conference on Infections in Leukaemia (ECIL-4): guidelines for diagnosis, prevention, and treatment of invasive fungal diseases in paediatric patients with cancer or allogeneic haemopoietic stem-cell transplantation. Lancet Oncol 15:e327- e340. http://dx.doi.org/10.1016/S1470-2045(14)70017-8.
    • (2014) Lancet Oncol , vol.15 , pp. e327-e340
    • Groll, A.H.1    Castagnola, E.2    Cesaro, S.3    Dalle, J.-H.4    Engelhard, D.5    Hope, W.6    Roilides, E.7    Styczynski, J.8    Warris, A.9    Lehrnbecher, T.10
  • 4
    • 60549086769 scopus 로고    scopus 로고
    • The CYP2C19 ultra-rapid metabolizer genotype influences the pharmacokinetics of voriconazole in healthy male volunteers
    • Wang G, Lei HP, Li Z, Tan ZR, Guo D, Fan L, Chen Y, Hu DL, Wang D, Zhou HH. 2009. The CYP2C19 ultra-rapid metabolizer genotype influences the pharmacokinetics of voriconazole in healthy male volunteers. Eur J Clin Pharmacol 65:281-285. http://dx.doi.org/10.1007/s00228-008-0574-7.
    • (2009) Eur J Clin Pharmacol , vol.65 , pp. 281-285
    • Wang, G.1    Lei, H.P.2    Li, Z.3    Tan, Z.R.4    Guo, D.5    Fan, L.6    Chen, Y.7    Hu, D.L.8    Wang, D.9    Zhou, H.H.10
  • 6
    • 72049130592 scopus 로고    scopus 로고
    • Voricona- zole pharmacokinetics and pharmacodynamics in children
    • Neely M, Rushing T, Kovacs A, Jelliffe R, Hoffman J. 2010. Voricona- zole pharmacokinetics and pharmacodynamics in children. Clin Infect Dis 50:27-36. http://dx.doi.org/10.1086/648679.
    • (2010) Clin Infect Dis , vol.50 , pp. 27-36
    • Neely, M.1    Rushing, T.2    Kovacs, A.3    Jelliffe, R.4    Hoffman, J.5
  • 9
    • 84898452706 scopus 로고    scopus 로고
    • Therapeutic drug monitoring (TDM) of antifungal agents: Guidelines from the British Society for Medical Mycology
    • Ashbee HR, Barnes RA, Johnson EM, Richardson MD, Gorton R, Hope WW. 2014. Therapeutic drug monitoring (TDM) of antifungal agents: guidelines from the British Society for Medical Mycology. J Antimicrob Chemother 69:1162-1176. http://dx.doi.org/10.1093/jac/dkt508.
    • (2014) J Antimicrob Chemother , vol.69 , pp. 1162-1176
    • Ashbee, H.R.1    Barnes, R.A.2    Johnson, E.M.3    Richardson, M.D.4    Gorton, R.5    Hope, W.W.6
  • 14
    • 27444447144 scopus 로고    scopus 로고
    • Galactomannan and computed tomography-based preemptive antifungal therapy in neutropenic patients at high risk for invasive fungal infection: A prospective feasibility study
    • Maertens J, Theunissen K, Verhoef G, Verschakelen J, Lagrou K, Verbeken E, Wilmer A, Verhaegen J, Boogaerts M, Eldere Van J. 2005. Galactomannan and computed tomography-based preemptive antifungal therapy in neutropenic patients at high risk for invasive fungal infection: A prospective feasibility study Clin Infect Dis 41:1242-1250.
    • (2005) Clin Infect Dis , vol.41 , pp. 1242-1250
    • Maertens, J.1    Theunissen, K.2    Verhoef, G.3    Verschakelen, J.4    Lagrou, K.5    Verbeken, E.6    Wilmer, A.7    Verhaegen, J.8    Boogaerts, M.9    Eldere, V.J.10
  • 15
    • 80052426714 scopus 로고    scopus 로고
    • Earlier response assessment in invasive aspergillosis based on the kinetics of serum aspergillus galactomannan: Proposal for a new definition
    • Nouér SA, Nucci M, Kumar NS, Grazziutti M, Barlogie B, Anaissie E. 2011. Earlier response assessment in invasive aspergillosis based on the kinetics of serum aspergillus galactomannan: Proposal for a new definition. Clin Infect Dis 53:671-676. http://dx.doi.org/10.1093/cid/cir441.
    • (2011) Clin Infect Dis , vol.53 , pp. 671-676
    • Nouér, S.A.1    Nucci, M.2    Kumar, N.S.3    Grazziutti, M.4    Barlogie, B.5    Anaissie, E.6
  • 17
    • 84863817675 scopus 로고    scopus 로고
    • Accurate detection of outliers and subpopulations with Pmetrics, a nonparametric and parametric pharmacometric modeling and simulation package for R
    • Neely MN, van Guilder MG, Yamada WM, Schumitzky A, Jelliffe RW. 2012. Accurate detection of outliers and subpopulations with Pmetrics, a nonparametric and parametric pharmacometric modeling and simulation package for R. Ther Drug Monit 34:467-476. http://dx.doi.org/10.1097/FTD.0b013e31825c4ba6.
    • (2012) Ther Drug Monit , vol.34 , pp. 467-476
    • Neely, M.N.1    Van Guilder, M.G.2    Yamada, W.M.3    Schumitzky, A.4    Jelliffe, R.W.5
  • 18
    • 39449117139 scopus 로고    scopus 로고
    • Voriconazole therapeutic drug monitoring in patients with invasive mycoses improves efficacy and safety outcomes
    • Pascual A, Calandra T, Bolay S, Buclin T, Bille J, Marchetti O. 2008. Voriconazole therapeutic drug monitoring in patients with invasive mycoses improves efficacy and safety outcomes. Clin Infect Dis 46:201-211. http://dx.doi.org/10.1086/524669.
    • (2008) Clin Infect Dis , vol.46 , pp. 201-211
    • Pascual, A.1    Calandra, T.2    Bolay, S.3    Buclin, T.4    Bille, J.5    Marchetti, O.6
  • 19
    • 31344478761 scopus 로고    scopus 로고
    • Investigation of the potential relationships between plasma voriconazole concentrations and visual adverse events or liver function test abnormalities
    • Tan K, Brayshaw N, Tomaszewski K, Troke P, Wood N. 2006. Investigation of the potential relationships between plasma voriconazole concentrations and visual adverse events or liver function test abnormalities. J Clin Pharmacol 46:235-243. http://dx.doi.org/10.1177/0091270005283837.
    • (2006) J Clin Pharmacol , vol.46 , pp. 235-243
    • Tan, K.1    Brayshaw, N.2    Tomaszewski, K.3    Troke, P.4    Wood, N.5


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.